Atea Pharmaceuticals Inc

Research Atea Pharmaceuticals Inc (AVIR) on Bullrun: market cap USD 368.92M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAVIR
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 368.92M
• Financial periodFY2025
• Net income-USD 158.00M

Valuation Snapshot

latest market cap is USD 368.92M.

About Atea Pharmaceuticals Inc

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.

Frequently asked questions

What is Atea Pharmaceuticals Inc's market cap?

Atea Pharmaceuticals Inc's market capitalization is USD 368.92M.

What does Atea Pharmaceuticals Inc do?

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.